688265 Shanghai Model Organisms Center, Inc.
- 20.45
- +0.18+0.89%
Shanghai Model Organisms Center, Inc. News
2024 Semi-Annual Report
2024 Semi-Annual Report Summary
Nanmo Bio (688265.SH) released its performance for the first half of the year, with a net loss of 9.1436 million yuan.
Nanmo Biotechnology (688265.SH) released its 2024 interim report, and during the reporting period, the company achieved revenue of 1...
Southern Mo Biotechnology (688265.SH): The net loss in the first half of the year was 9.1436 million yuan.
On August 28, Ge Long Hui announced its 2024 interim report, reporting a revenue of 0.177 billion yuan, a year-on-year decrease of 2.17%; net income attributable to shareholders of the listed company was -9.1436 million yuan.
Gelonghui Fund Daily Report | Public fund baijiu holdings have dropped to as low as 10%! Wan Minyuan increased holdings.
Focus on the latest news in the fund.
Nanmo Biotech (688265.SH): Repurchased 0.4082 million shares of the company's stock for the first time.
On July 29th, Gelunhui announced that on July 29th, 2024, the company repurchased 0.408244 million shares of the company for the first time through the Shanghai Stock Exchange trading system by centralized bidding, accounting for 0.5236% of the company's total share capital of 77,963,513 shares. The minimum price of the repurchase transaction was 21.37 yuan/share, and the highest price was 22.50 yuan/share. The total amount of funds paid was 9.082418 million yuan (excluding transaction fees such as taxes and transaction commissions).
Nanmo Biotech (688265.SH) plans to repurchase its shares at a cost of 15 to 30 million yuan.
On July 25th, Gelonhui reported that Nammu Biology (688265.SH) plans to buy back shares for an amount not less than RMB 15 million and not more than RMB 30 million, with a share buyback price not exceeding RMB 32 per share, in order to maintain the company's value and shareholder equity.
Shanghai Model Organisms Center CFO Steps Down
Nanmo Biotech (688265.SH): The repurchase period has expired and a total of 1.0119% of the company's shares have been repurchased
Gelonghui, May 22丨Nanmo Biotech (688265.SH) announced that as of May 22, 2024, the company's share repurchase period has expired, and the implementation of the share repurchase plan has been completed. The company bought back 788,912 shares of the company through centralized bidding transactions through the Shanghai Stock Exchange trading system, accounting for 1.0119% of the company's total share capital of 77,963,513 shares. The highest price of the repurchase transaction was 29.98 yuan/share, the lowest price was 23.90 yuan/share, and the total capital paid was RMB 21.453.59 million (excluding taxes, transaction commissions, etc.)
Nanmo Biotech (688265.SH): Repurchase 1.0119% of shares through centralized bidding
Gelonghui, May 7, 丨 Nanmo Biotech (688265.SH) announced that as of April 30, 2024, the company had repurchased 788,912 shares through the Shanghai Stock Exchange trading system, accounting for 1.0119% of the company's total share capital of 77,963,513 shares. The highest price of the repurchase transaction was 29.98 yuan/share, the lowest price was 23.90 yuan/share, and the total amount of capital paid was RMB 21.453.59 million (excluding transaction fees such as taxes and transaction fees).
Nanmo Biotech (688265.SH) announced first-quarter results with a net loss of 12.8971 million yuan
Nanmo Biotech (688265.SH) released its report for the first quarter of 2024. During the reporting period, the company achieved an operating income of 8...
Nanmo Biotech (688265.SH): A total cost of 14.964 million yuan to buy back 0.69% of the shares
Gelonghui, April 1, 丨 Nanmo Biotech (688265.SH) announced that as of March 31, 2024, the company had repurchased 538,911 shares through the Shanghai Stock Exchange trading system, accounting for 0.6912% of the company's total share capital of 77,963,513 shares. The highest price of the repurchase transaction was 29.98 yuan/share, the lowest price was 26.03 yuan/share, and the total amount of capital paid was RMB 14.96.44.42 million (excluding transaction fees such as taxes and transaction fees).
Nanmo Biotech (688265.SH): 1.1283% of shares have been repurchased
Gelonghui, March 26, 丨 Nanmo Biotech (688265.SH) announced that as of March 25, 2024, the company had repurchased a total of 889.6.67 million shares through centralized bidding transactions, accounting for 1.1283% of the company's total share capital, an increase of 0.5119 percent compared with the previous disclosure. The highest purchase price was 40.99 yuan/share, the lowest price was 26.03 yuan/share, and the total amount paid was 28.412.58 million yuan (excluding transaction fees such as taxes and transaction fees).
Nanmo Biotech (688265.SH): 293,000 shares repurchased for the first time
Gelonghui, Feb. 29丨Nanmo Biotech (688265.SH) announced that on February 29, 2024, the company repurchased 29,257 shares of the company's shares for the first time through centralized bidding transactions, accounting for 0.0375% of the company's total share capital of 77,963,513 shares. The highest price of the repurchase transaction was 27.72 yuan/share, the lowest price was 26.95 yuan/share, and the total amount of capital paid was RMB 796,734.92 (excluding tax, transaction fees and other transaction fees).
Nanmo Biotech (688265.SH): Plans to spend 15 million yuan to 30 million yuan to buy back shares
On February 23, Gelonghui Biotech (688265.SH) announced that the company plans to use its own funds to repurchase the company's shares through centralized bidding transactions to protect the company's value and shareholders' rights. The total capital to be repurchased shall not be less than RMB 15 million (inclusive), not more than RMB 30 million (inclusive), and the repurchase price shall not exceed RMB 43 per share (inclusive).
Nanmo Biotech (688265.SH): A total of 432,500 shares have been repurchased as of January 31
Gelonghui, Feb. 2: Nanmo Biotech (688265.SH) announced that as of January 31, 2024, 432,495 shares of the company had been repurchased through centralized bidding transactions, accounting for 0.5547% of the company's total share capital of 77,963,513 shares. The highest repurchase transaction price was 40.99 yuan/share, the lowest price was 27.95 yuan/share, and the total amount of capital paid was RMB 15.9807 million (excluding transaction fees such as taxes and transaction fees).
Nanmo Biotech (688265.SH): Currently, the overseas business layout is still dominated by BD
Gelonghui, Feb. 2: Nanmo Biotech (688265.SH) recently said during a survey receiving institutional investors that at present, the overseas business layout is still mainly BD. The company will continue to expand overseas BD teams, especially increasing BD recruitment and training in biomedical developed regions such as Boston and California, increasing overseas market expansion efforts, hoping to continue to increase the growth rate and share of overseas revenue. In addition, the US subsidiary has purchased real estate in Texas, USA. Combined with the current market demand situation and the investment impact brought about by the expansion of production capacity, it has not invested in renovation yet. Some overseas leasing positions can meet current demand.
Nanmo Biology (688265.SH): Currently, the company has 6 production and R&D bases in Shanghai
Gelonghui, Feb. 2: Nanmo Biotech (688265.SH) recently said during a survey receiving institutional investors that at present, the company has 6 production and development bases in Shanghai (Banxia Road, Jinke Road, Harley Road, Jinshan Phase I, Jinshan Phase II, Shangke Road), as well as the Guangdong Zhongshan base covering the South China region and the Beijing Beichen Road base covering North China. There are no plans to add a large amount of production capacity in the short term. In the future, some high-cost bases will be replaced with low-cost bases according to strategic plans. Currently, the capacity utilization rate is about 70%. In the future, it will be further adjusted according to the needs of downstream customers
What You Can Learn From Shanghai Model Organisms Center, Inc.'s (SHSE:688265) P/SAfter Its 27% Share Price Crash
Nanmo Biotech (688265.SH): Pre-loss of 16 million yuan to 24 million yuan in 2023
Gelonghui, January 30丨Nanmo Biotech (688265.SH) announced its 2023 annual results forecast. According to preliminary estimates by the company's finance department, it is expected to achieve operating income of 36,000,000 yuan to 380.01 million yuan in 2023. Compared with the same period of the previous year (statutory disclosure data), it will increase 57.034,800 yuan to 77.034 million yuan, with a change ratio of 18.83% to 25.43%. The net profit attributable to the owners of the parent company is expected to be -24.00 million yuan to -16 million yuan in 2023, and above
Analysis
Price Target
No Data
